Sermorelin Medicaid Coverage by State Tier: What You Will Actually Pay in 2026

Why No State Medicaid Program Covers Sermorelin

Sermorelin coverage is zero across all 50 state Medicaid programs. That outcome is not arbitrary, it follows directly from how federal Medicaid law treats compounded drugs and from sermorelin's regulatory history.

The Compounding Pharmacy Exclusion

Federal Medicaid law under 42 U.S.C. § 1396r-8 defines "covered outpatient drugs" as products with FDA approval and a valid rebate agreement with CMS. Compounded medications dispensed by 503A pharmacies, the only legal source of sermorelin acetate today, are not FDA-approved finished drug products. The FDA's guidance on 503A compounding makes this distinction explicit: a compounded preparation is made for an individual patient and bypasses the New Drug Application process entirely. [1]

Because sermorelin cannot enter a rebate agreement, it cannot appear on any state Preferred Drug List. No prior authorization pathway exists to override this. The exclusion is structural.

Why Sermorelin Is Only Available as a Compounded Drug

Serono's branded sermorelin product Geref Diagnostic was withdrawn from the U.S. Market in 2008 for commercial, not safety, reasons. The FDA confirmed the withdrawal was not due to safety or efficacy concerns. [2] Without an approved sponsor, sermorelin re-entered clinical use exclusively through compounding pharmacies operating under section 503A of the Federal Food, Drug, and Cosmetic Act. [3]

The FDA classifies sermorelin as a "bulk drug substance" that may be used in compounding under specific conditions. Prescribers and patients must understand that the quality, sterility, and potency of compounded sermorelin vary by pharmacy, unlike standardized commercial products. [4]

State-by-State Tier Classification

Because Medicaid exclusion is uniform, there are no meaningful state tiers for coverage. The table below classifies states by a different, more clinically useful variable: the strictness of their state pharmacy board regulations for 503A compounding, which affects how many licensed compounding pharmacies operate locally and therefore affects price.

| Tier | States | Effect on Patient Cost | |---|---|---| | Tier 1, High compounding density | CA, TX, FL, NY, PA | More competition; lower average price ($150 to $220/month) | | Tier 2, Moderate compounding density | OH, IL, GA, NC, WA, CO, AZ, MN, MI, VA | Mid-range pricing ($200 to $300/month) | | Tier 3, Low compounding density | Most remaining states, especially rural Mountain West and upper Plains | Higher average price ($280 to $400/month); telehealth pharmacies often cheaper |

Patients in Tier 3 states frequently pay less by ordering through a telehealth platform that contracts with a national 503A pharmacy than by using a local compounding pharmacy. [5]

How Federal Law Shapes Sermorelin Access in 2026

The 503A vs. 503B Distinction

The FDA distinguishes between 503A pharmacies (patient-specific compounding, no sterile outsourcing license required) and 503B outsourcing facilities (large-scale sterile compounding, FDA-registered). [6] Most sermorelin prescribed through telehealth platforms is dispensed by 503A pharmacies. A small number of 503B facilities also compound sermorelin, which may offer modestly more consistent sterility testing. [7]

For patients, the practical difference is minimal in routine clinical use. Both categories are excluded from Medicaid. Both require a valid individual prescription.

Controlled Substance and DEA Classification

Sermorelin is not a DEA-scheduled controlled substance. [8] This means prescribers do not need a DEA registration separate from their standard medical license to prescribe it, and pharmacies do not face controlled-substance dispensing quotas. That regulatory simplicity makes telehealth prescribing straightforward compared to, for example, testosterone cypionate.

The Off-Label Adult Use Question

The FDA cleared sermorelin (as Geref) specifically for diagnosing growth hormone deficiency in children and for treating growth failure in prepubertal children with documented GH deficiency. [9] Adult use, particularly for age-related GH decline, body composition, or sleep quality, is off-label. Medicaid does not cover off-label uses of compounded drugs. Even if sermorelin re-entered the commercial market, adult anti-aging or body composition indications would face formulary exclusion under most state Medicaid programs. [10]

The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults states: "We recommend against the use of GH therapy in healthy older adults to prevent or reverse the effects of aging." [11] That guideline position reinforces why no public payer covers adult sermorelin therapy.

Medicare Coverage: The Same Exclusion Applies

Medicare Part D covers FDA-approved outpatient prescription drugs. Compounded sermorelin fails that threshold for exactly the same reasons it fails Medicaid. [12]

Medicare Part B covers certain injectable drugs administered in a physician's office, but only if they are FDA-approved and medically necessary for a covered indication. Off-label adult sermorelin therapy meets neither criterion. [13]

Patients who are dually eligible for Medicare and Medicaid have no additional pathway. Both programs exclude compounded sermorelin categorically.

What Sermorelin Actually Costs Without Coverage

Dose-Dependent Pricing

Sermorelin doses in adult clinical practice typically range from 200 mcg to 500 mcg injected subcutaneously each night before sleep, based on common prescribing patterns in hormone optimization practice. Some protocols use doses up to 1,000 mcg nightly. The monthly cost scales with dose.

At 200 mcg/night (a 6,000 mcg monthly supply), a 503A pharmacy in a Tier 1 state typically charges $150 to $180. At 500 mcg/night (15,000 mcg monthly), the same pharmacy may charge $250 to $320. [14]

Compounding Pharmacy Price Variation

A 2021 analysis of compounded hormone prices published in JAMA found meaningful price variation across 503A pharmacies for the same hormone preparation, with some pharmacies charging more than twice the price of others for identical formulations. [15] Sermorelin follows the same pattern. Patients should obtain quotes from at least three pharmacies before filling.

Telehealth Platform Pricing

Telehealth platforms that operate in-house pharmacy networks or have negotiated contracts with 503A pharmacies often offer bundled pricing that includes the provider consultation, prescription, and medication. All-in monthly costs through these platforms commonly run $199 to $299, which may be lower than the sum of a separate endocrinologist visit plus local pharmacy fill. [16]

The HealthRX Access Decision Framework for patients seeking sermorelin in 2026:

1. Confirm with your prescriber that your IGF-1 level, clinical history, and goals meet the threshold for a sermorelin prescription.
2. Get quotes from at least two local 503A compounding pharmacies and one national telehealth-affiliated pharmacy.
3. If your state is Tier 3 (low compounding density), default to a telehealth platform with a contracted national pharmacy.
4. Pay with HSA or FSA dollars to recover 22 to 37 cents on every dollar spent (your marginal tax rate).
5. Ask your prescriber whether ipamorelin/CJC-1295 is an appropriate clinical alternative, compounded combination peptides sometimes carry lower per-mcg costs than sermorelin alone.

How to Get Sermorelin Cheaper: Every Legal Pathway

HSA and FSA Payments

Sermorelin is eligible for Health Savings Account (HSA) and Flexible Spending Account (FSA) payment when prescribed by a licensed provider for a diagnosed medical condition. The IRS defines eligible medical expenses under Section 213(d) of the Internal Revenue Code as expenses for "diagnosis, cure, mitigation, treatment, or prevention of disease." [17] A compounded prescription drug dispensed by a licensed pharmacy meets this definition.

The effective discount from HSA/FSA payment depends on your marginal federal income tax rate plus state income tax. At a combined 30% marginal rate, a $250/month sermorelin prescription costs an effective $175 after tax savings. That is a straightforward 30% discount that requires no negotiation.

FSA funds have use-it-or-lose-it rules. Plan timing of your prescription fill to avoid forfeiting unused FSA balances. HSA funds roll over indefinitely. [18]

Telehealth Membership Models

Several telehealth platforms offer subscription models where patients pay a flat monthly fee covering provider access, ongoing monitoring, and medication. These models typically charge $150 to $250 per month all-in, compared to $300 to $500 when booking individual endocrinology appointments plus separate pharmacy costs. The savings derive from the telehealth model's lower overhead, not from any insurance subsidy.

Compounding Pharmacy Shopping and Formulary Alternatives

Prices at 503A compounding pharmacies are not regulated. Calling three pharmacies and asking for a specific formulation and vial size often produces quotes varying by $50 to $100 per month for identical products. National 503A pharmacies that serve telehealth platforms may undercut local pharmacies by 20 to 40% due to volume. [19]

Some prescribers substitute sermorelin with ipamorelin/CJC-1295 (a growth hormone-releasing peptide combination) when cost is a barrier. These peptides act on overlapping pathways and are also available only through compounding pharmacies, but their per-dose cost is sometimes lower. The clinical profiles differ, so any substitution requires prescriber judgment. [20]

Manufacturer and Patient Assistance Programs

No manufacturer patient assistance program exists for compounded sermorelin because there is no commercial manufacturer. The branded product Geref has been discontinued since 2008. [2] Patients should be skeptical of any program claiming to offer "manufacturer discounts" on sermorelin.

Monitoring Requirements and Their Cost Implications

Appropriate prescribing of sermorelin involves baseline and follow-up IGF-1 levels (insulin-like growth factor 1), which are the accepted surrogate marker for GH axis activity. [21] A serum IGF-1 test costs $40 to $120 at commercial labs without insurance coverage.

The Endocrine Society recommends that growth hormone therapy in adults be titrated to maintain IGF-1 in the mid-normal range for age and sex. [22] Labs drawn every 3 to 6 months add $80 to $480 annually to the total cost of therapy. These lab costs are also HSA/FSA-eligible. [17]

A thyroid panel and fasting glucose are reasonable at baseline because GH secretagogues can modestly affect glucose metabolism in some patients. [23] The FDA's prescribing information for recombinant human GH (somatropin) notes glucose intolerance as a potential class effect, and sermorelin, as a GH secretagogue, shares this theoretical concern. [24]

Prior Authorization and Appeals: Not Applicable, but Here Is Why

Patients sometimes ask whether a prior authorization appeal can force Medicaid coverage of sermorelin. It cannot. Prior authorization is a utilization management tool applied to drugs already on a formulary. It does not apply to categorically excluded drugs.

A Medicaid enrollee could theoretically file a grievance under 42 C.F.R. § 438.400 if they believe a service was wrongly denied. [25] However, the denial of a non-formulary compounded drug is not a wrongful denial, it reflects the statutory definition of covered outpatient drugs. Appeals have not succeeded for compounded sermorelin in any published CMS adjudication.

If a patient has a documented diagnosis of adult-onset growth hormone deficiency confirmed by two GH stimulation tests, they may qualify for coverage of FDA-approved recombinant human GH (somatropin, e.g., Norditropin or Genotropin). That pathway is entirely separate from sermorelin and involves a different diagnostic workup and treatment protocol. [22]

Telehealth Prescribing Field in 2026

The DEA's 2023 proposed rules on telemedicine prescribing, updated through subsequent rulemaking, affect controlled substances but not sermorelin, which carries no DEA schedule. [26] Sermorelin can be legally prescribed via synchronous or asynchronous telehealth in most states without a prior in-person examination, subject to individual state medical board rules.

California, for example, requires that a patient-provider relationship be established before prescribing, but does not require an in-person visit for non-controlled substances. Texas imposes a face-to-face or synchronous audio-video requirement for the initial prescription of any medication. Patients should confirm their state's telehealth prescribing rules before starting a telehealth-based sermorelin protocol. [27]

Safety Context: Why Coverage Decisions Are Not the Only Consideration

Access and affordability are real barriers, but they should not overshadow the clinical question of whether sermorelin is appropriate for a specific patient. The evidence base for adult sermorelin therapy is smaller than for recombinant GH, and long-term outcome data are limited.

A 2019 Cochrane review of GH secretagogues in adults found improvements in lean body mass and reductions in fat mass across trials, but noted that most studies were short-term and underpowered for hard clinical outcomes like fracture, cardiovascular events, or mortality. [28] Mean lean mass gains across included trials ranged from 1.5 to 3.0 kg over 6 to 12 months. That magnitude is clinically meaningful for some patients and irrelevant for others, depending on their goals.

Adverse effects associated with GH secretagogues include fluid retention, joint discomfort, and transient elevations in fasting glucose. [29] These effects are generally dose-dependent and resolve with dose reduction. Patients with active malignancy or diabetic retinopathy should not use sermorelin or any GH secretagogue. [30]